| Product Name | (Pyr1)-Apelin-13 (human, bovine) |
| Synonyms | (Glp1)-Apelin-13, [pGlu1]-Apelin-13, Pyroglutamyl apelin-13, Pyr-apelin-13 |
| CAS Number | 217082-60-5 (native Apelin-13 with free glutamine is 217082-58-1) |
| Sequence (3-Letter) | pGlu-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe (N-terminal pyroglutamate) |
| Sequence (1-Letter) | pGlu-RPRLSHKGPMPF (from Apelin-13 QRPRLSHKGPMPF, Gln1 → pyroglutamate) |
| Molecular Formula | C₆₉H₁₀₈N₂₂O₁₆S |
| Molecular Weight | 1533.8 |
| Category | Drug Peptide – Apelin Receptor (APJ) Agonist |
| Purity | ≥98% (by HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate or TFA (salt form per specification) |
| Peptide Content | ≥80% (per specification) |
| Solubility | Soluble in water |
| Storage | -20°C, desiccated, protected from light |
| Available Scale | mg – g (research quantities; larger scale on enquiry) |
| QC Documentation | COA, HPLC, MS identity (additional API/regulatory and reference-standard documentation on request) |
| Usage | For research and pharmaceutical development use, and as a reference standard or active pharmaceutical ingredient for manufacturing. Not for human or veterinary use; not for sale to patients. Any therapeutic use is subject to applicable regulatory approval. |
(Pyr1)-Apelin-13, also written (Glp1)-Apelin-13 or pyroglutamyl apelin-13, is a thirteen-residue peptide and the main active form of apelin-13 found in human heart and blood (CAS 217082-60-5). Its sequence is pGlu-RPRLSHKGPMPF, the same as apelin-13 but with the first glutamine turned into a pyroglutamate, which makes it more stable. It is an endogenous agonist of the apelin receptor. We supply it as a white powder for research and pharmaceutical development.
(Pyr1)-Apelin-13 binds and activates the apelin receptor, also called APJ, a G-protein-coupled receptor found in the heart, blood vessels, and other tissues. Through this receptor the apelin system helps regulate the strength of heart contraction, the widening of blood vessels, fluid balance, and aspects of metabolism. The pyroglutamate at the start of the peptide protects it from being trimmed by enzymes, so it lasts longer than plain apelin-13.
(Pyr1)-Apelin-13 is used in research as a potent, selective apelin-receptor agonist, mainly to study cardiovascular function and the apelin signalling system, and it is also used as a reference standard. These are research uses only; the material we supply is for research and pharmaceutical manufacturing use, and is not for human or veterinary use and not for sale to patients.
We supply (Pyr1)-Apelin-13 with a certificate of analysis, HPLC purity data, and mass-spec identity confirmation. Additional documentation for API and regulatory work is available on request, and salt form and purity can be set to your specification, including reference-standard grade.
Yes. We manufacture (Pyr1)-Apelin-13 in-house and supply from research quantities up to larger batches. Contact us with your required purity, salt form, and quantity for a quote.
(Pyr1)-Apelin-13, also known as (Glp1)-Apelin-13 or pyroglutamyl apelin-13, is the main active form of the signalling peptide apelin-13 and a potent agonist of the apelin receptor. It is widely used as a research peptide, and we supply it as a raw material for research and pharmaceutical development.
(Pyr1)-Apelin-13 is a thirteen-residue peptide, pGlu-RPRLSHKGPMPF, corresponding to the C-terminal portion of the apelin precursor. It has the same sequence as apelin-13 except that the N-terminal glutamine is cyclised to a pyroglutamate residue; this modification protects the peptide from enzymatic trimming and makes it the dominant, longer-lived form in human heart and plasma. The sequence is shared by human and bovine apelin. Its CAS number is 217082-60-5 (the native glutamine form is 217082-58-1), its molecular formula is C69H108N22O16S, and its molecular weight is about 1534.
(Pyr1)-Apelin-13 binds and activates the apelin receptor, also called APJ or APLNR, a G-protein-coupled receptor expressed in the heart, blood vessels, and other tissues. Through this receptor the apelin system participates in regulating the force of cardiac contraction, the dilation of blood vessels, fluid balance, and aspects of metabolism. The pyroglutamate cap at the N-terminus is what makes this form more resistant to breakdown than plain apelin-13.
(Pyr1)-Apelin-13 is used in research as a potent and selective apelin-receptor agonist, mainly to study cardiovascular physiology and the apelin signalling system, and as a reference standard. These are research uses described here as scientific background. The material supplied by SynPeptide is intended for research and pharmaceutical manufacturing, is not for human or veterinary use, and is not for sale to patients; any therapeutic use would be subject to applicable regulatory approval.
We supply (Pyr1)-Apelin-13 with a certificate of analysis, HPLC purity data, and mass-spectrometry identity confirmation, and can provide it at reference-standard grade. Further documentation to support active pharmaceutical ingredient and regulatory work is available on request, and purity and salt form can be set to your specification.
We manufacture (Pyr1)-Apelin-13 by solid-phase synthesis, including the N-terminal pyroglutamate, and supply it from research quantities through to larger batches. For related capabilities, see drug peptides, custom peptide synthesis, peptide modification, and our catalog peptides. Material is supplied for research and pharmaceutical manufacturing use only.
